These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6285557)

  • 21. Synthesis of antimony complexes of yeast mannan and mannan derivatives and their effect on Leishmania-infected macrophages.
    Cantos G; Barbieri CL; Iacomini M; Gorin PA; Travassos LR
    Biochem J; 1993 Jan; 289 ( Pt 1)(Pt 1):155-60. PubMed ID: 8424752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Species-specific antimonial sensitivity in Leishmania is driven by post-transcriptional regulation of AQP1.
    Mandal G; Mandal S; Sharma M; Charret KS; Papadopoulou B; Bhattacharjee H; Mukhopadhyay R
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003500. PubMed ID: 25714343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An in vitro model for screening antileishmanial drugs: the human leukaemia monocyte cell line, THP-1.
    Gebre-Hiwot A; Tadesse G; Croft SL; Frommel D
    Acta Trop; 1992 Aug; 51(3-4):237-45. PubMed ID: 1359751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of Leishmania donovani promastigote DNA topoisomerase I and human monocyte DNA topoisomerases I and II by antimonial drugs and classical antitopoisomerase agents.
    Walker J; Saravia NG
    J Parasitol; 2004 Oct; 90(5):1155-62. PubMed ID: 15562618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leishmania spp.: development of pentostam-resistant clones in vitro by discontinuous drug exposure.
    Grögl M; Oduola AM; Cordero LD; Kyle DE
    Exp Parasitol; 1989 Jul; 69(1):78-90. PubMed ID: 2543590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of meglumine antimoniate, a pentavalent antimonial drug, on Leishmania promastigotes.
    Moreira ES; Petrillo-Peixoto ML
    Braz J Med Biol Res; 1991; 24(5):459-69. PubMed ID: 1823261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Methylglucamine antimoniate and sodium stibogluconate in the treatment of leishmaniasis. Study of 16 cases].
    Bourée P; Anciaux ML; Taugourdeau P
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):607-10. PubMed ID: 3003657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of antileishmanial agents against amastigotes in human monocyte-derived macrophages and in mouse peritoneal macrophages.
    Berman JD; Lee LS
    J Parasitol; 1984 Apr; 70(2):220-5. PubMed ID: 6088749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection.
    Rojas R; Valderrama L; Valderrama M; Varona MX; Ouellette M; Saravia NG
    J Infect Dis; 2006 May; 193(10):1375-83. PubMed ID: 16619185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pentavalent antimonial inhibition of the osmotic effect of oxytocin on the isolated toad bladder.
    Gagliardi AR; Veiga JP; Rosa TT; Marsden PD
    Braz J Med Biol Res; 1985; 18(4):567-71. PubMed ID: 3015305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of glucantime on field and patient isolates of New World Leishmania: use of growth parameters of promastigotes to assess antimony susceptibility.
    Moreira ES; Anacleto C; Petrillo-Peixoto ML
    Parasitol Res; 1998 Sep; 84(9):720-6. PubMed ID: 9766900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy of trypanosomiasis: the potentiation of antimonial compounds by difluoromethylornithine (DFMO).
    Jennings FW
    Trop Med Parasitol; 1991 Jun; 42(2):135-8. PubMed ID: 1654590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Schistosoma mansoni: effects of anesthetics and antimonial drugs on worm shift in the mouse.
    da Cunha-Melo JR; Coelho PM
    Rev Inst Med Trop Sao Paulo; 1986; 28(4):267-70. PubMed ID: 3031809
    [No Abstract]   [Full Text] [Related]  

  • 34. Sensitivity of Leishmania viannia panamensis to pentavalent antimony is correlated with the formation of cleavable DNA-protein complexes.
    Lucumi A; Robledo S; Gama V; Saravia NG
    Antimicrob Agents Chemother; 1998 Aug; 42(8):1990-5. PubMed ID: 9687395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimony susceptibility of Leishmania isolates collected over a 30-year period in Algeria.
    Eddaikra N; Ait-Oudhia K; Kherrachi I; Oury B; Moulti-Mati F; Benikhlef R; Harrat Z; Sereno D
    PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006310. PubMed ID: 29561842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-administration of glycyrrhizic acid with the antileishmanial drug sodium antimony gluconate (SAG) cures SAG-resistant visceral leishmaniasis.
    Bhattacharjee A; Majumder S; Majumdar SB; Choudhuri SK; Roy S; Majumdar S
    Int J Antimicrob Agents; 2015 Mar; 45(3):268-77. PubMed ID: 25600891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate.
    Chulay JD; Fleckenstein L; Smith DH
    Trans R Soc Trop Med Hyg; 1988; 82(1):69-72. PubMed ID: 2845611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pentavalent antimonial treatment in mucosal leishmaniasis.
    Sampaio RN; Sampaio JH; Marsden PD
    Lancet; 1985 May; 1(8437):1097. PubMed ID: 2860306
    [No Abstract]   [Full Text] [Related]  

  • 39. Leishmania infantum: stage-specific activity of pentavalent antimony related with the assay conditions.
    Carrió J; de Colmenares M; Riera C; Gállego M; Arboix M; Portús M
    Exp Parasitol; 2000 Jul; 95(3):209-14. PubMed ID: 10964649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leishmania (V.) guyanensis: isolation and characterization of glucantime-resistant cell lines.
    Ferreira-Pinto KC; Miranda-Vilela AL; Anacleto C; Fernandes AP; Abdo MC; Petrillo-Peixoto ML; Moreira ES
    Can J Microbiol; 1996 Sep; 42(9):944-9. PubMed ID: 8864217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.